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ABSTRACT 
Objectives: To suggest an acceptable and generic theoretical framework for involving 
various types of users in the medical device technology (MDT) development process 
(MDTDP).  
Methods: The authors propose a theoretical framework suggesting different routes, 
methods and stages through which various types of medical device users can be 
involved in the MDTDP.  
Results: The suggested framework comprises two streams of users’ involvement in 
MDT development i.e. what might be called the end users’ stream and the professional 
users’ stream for involving these two groups respectively in the process of developing 
both simple and more complex and innovative medical devices from conceptualisation 
through to the market deployment. This framework implies various methods that can 
be used for users’ involvement at different stages of the MDT lifecycle. To illustrate the 
application of the framework, a number of MDT development scenarios and device 
exemplars are presented.  
Conclusions: Development of medical devices from users’ perspectives requires not 
only the involvement of healthcare professionals but also that of the ultimate end users 
i.e. patients, people with disabilities and/or special needs, and their caregivers. The 
evidence shows that such end users quickly discard devices that do not fulfil their 
personal expectations, even though both manufacturers and healthcare professionals 
may consider those end users’ requirements met. Developers and manufacturers need 
to recognise this potent potential discrepancy between the parties involved, and involve 
end users and professional healthcare staff directly in the MDTDP. The framework, the 
authors contend, is a step forward in helping medical device manufacturers plan and 
make decisions about users’ involvement at different stages of the MDTDP. 
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INTRODUCTION 
Medical device technologies (MDTs) include medical devices and assistive devices (35), 
which have been defined elsewhere(14;38). There are a range of, often competing 
perspectives, concerning MDT such as regulators’ perspectives, manufacturers’ 
perspectives and users’ perspectives. All these perspectives are important to assess and 
synthesize, but users’ perspectives is particularly important for the success of a device. 
Users of MDTs are not homogeneous as they are often implicitly considered to be, but 
are constituted by different types and groups of people such as healthcare professionals, 
carers and end users e.g. patients, people with disabilities and/or special needs and 
elderly people, with different roles and interests (35). Involvement of the users is 
essential because they expect that the medical device that is supplied to them, or that 
they buy and use, fulfills their personal needs and requirements, which may indeed vary 
from one user to another, especially in the case of end users. The most effective way of 
developing MDTs from users’ perspective therefore can be done by involving the 
healthcare professionals as well as the end users. For devices that are intended for the 
use by end users, views of and acceptance by end users is crucial to the device’s role and 
longevity, no matter how well the device is manufactured, and how strongly it is 
recommended by healthcare professionals.   
 There is published evidence that end users’ involvement in the MDT 
development process (MDTDP) is associated with several substantial advantages for 
manufacturers. For example, the generation of ideas for new products and product 
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innovation; access to users’ actual requirements and expectations; a reduction in 
development costs; an improvement in device design, usability and safety; and the 
identification of potential problems at an early stage of the device development cycle, 
thus limiting costly device modifications and a reduction in device recalls (25;34). 
Manufacturers therefore need to engage with the range of users of MDTs and involve 
them, as early as possible, in the development process (12).  
 Up to now evidence on users’ involvement in the MDTDP is clearly focused on 
the views of healthcare professionals, particularly clinicians and nurses, while other 
types of MDT users, especially end users, such as patients, people with disabilities 
and/or special needs, elderly people and carers, particularly lay carers, are less likely to 
be involved in the process (4;11, p.173;25;33). The apparently minimal involvement of 
the end users (who we also call as non-healthcare professional users), can be for 
various reasons including their personal characteristics and a need for supporting, 
preparing and training them to enable their involvement in the MDTDP (34).  
 According to Andre et al (2), user involvement depends and/or is facilitated by 
the availability of an appropriate framework. In relation to MDT, a number of 
frameworks have been used. For example, the technology transfer model (36); the 
economic evaluation in health technology assessment (32); a framework for the 
development and evaluation of randomised controlled trials (8;26); a model of user 
engagement in medical device development (15), and the integration of a Bayesian 
framework in the medical device development cycle (37). However, no universal and 
formal framework for the involvement of users, especially end users, in the process of 
MDT manufacturing from concept development through to the market deployment has 
been reported in the literature (4;25;33). In the absence of an acceptable and proper 
framework, a meaningful users’ involvement cannot occur systematically across the 
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medical device sector but it will take place haphazardly. This has had, and is likely to 
have, negative repercussions for both manufacturers and users of MDTs, for example 
the continuous abandonment of the devices by their users (3). There is therefore a need 
for an acceptable and generic framework for involving various types of users in the 
MDTDP. The authors therefore propose such a framework in this paper. However, 
before presenting our conceptual framework, we briefly describe some key concepts, i.e. 
stages of MDT development cycle, methods of involving users and types of MDT users, 
on which the framework is based. 
Stages in MDT Lifecycle Relevant for Involving Users  
The lifecycle of a medical device can be divided into several stages, over which there is 
some debate. Cooper and Kleinschmidt (9) described 13 stages in the lifecycle of a 
medical device, which were modified to 12 stages by Rochford and Rudelius (31). 
Elsewhere, seven stages of the medical device lifecycle have been mentioned (38). Shah 
and Robinson (33) reviewed the different stages of medical device lifecycle reported in 
a wide range of analyses and determined that the various stages of the medical device 
lifecycle can be placed into five key phases:  
 
 Stages of the Medical Device Lifecycle 
 Concept stage (idea generation and concept development) 
 Design stage (device (re-)design and prototype development)  
 Testing and trials stage (prototype testing in-house and trials in the real field) 
 Production stage (device production based on business and commercial rational)  
 Deployment stage (product launch and use in the market and post-deployment 
user feedback) 
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Literature shows that users can be involved at four stages, i.e. concept, design, testing 
and trials, and deployment stages, of the above-mentioned five stages (33). We 
therefore suggest these four stages can best be used to develop our theoretical 
framework for involving users in MDTDP (Figure 1). 
 
Methods for Involving Users 
Recent published work suggests several methods that have been used for involving 
different types of users in the MDTDP (4;25;33). For example, interviews, focus groups, 
usability tests, customer feedback, cognitive walkthrough, cognitive task analysis, users 
and producers seminars and field observation methods used for involving the end 
users, such as patients, people with disabilities and/or special needs and lay carers, and 
the professional users, e.g., physicians, general practitioners, surgeons, nurses, 
cardiologists, radiologists, MRI professionals and physicists) in the development 
process of different types of MDTs.  For instance, an inhaler (1), assistive devices such 
as robotic aids, wheel chairs, wheeled mobility devices  (3;6;7;20;28), ventilators (13), 
teleradiology system (16),  neuromagnetometer (17;27), intraventicular blood pump 
(18), telemedicine system (19), patient monitoring system (22), patient-controlled 
analgesia pump (23), and infusion pumps (12;29;39).  
 In our theoretical framework, we will be suggesting that many of the methods 
mentioned above can be successfully and directly deployed in relation to the 
involvement of the professional users and the end users at four different stages of the 
MDT lifecycle (Figure 1).  
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Figure 1. Theoretical framework for involving users in the medical device technology development process: streams, methods and stages 
  
Users of Medical Device Technologies 
Primary users of medical devices can be divided, based on their professional and 
personal traits, into different groups, such as healthcare professionals, patients, people 
with disabilities and/or special needs, elderly people and carers i.e. professional and lay 
carers (35). In addition, Shah and Robinson (35) are of the opinion that professional 
people use the devices for the benefit of patients, people with disabilities and/or special 
needs and elderly people – whom they describe collectively as ‘end users’.  
 In order to clarify further the term ‘user’ here, which often in practice has led to 
confusion in studies as to whom exactly is referred to by the term, we think medical 
device users can be  classified into two major categories i.e. end users (non-professional 
users) and professional users. The former category may include patients, people with 
disabilities and/or special needs, elderly people and lay carers, essentially those non 
health care professionals directly using devices, whilst the professional users may 
include a wide range of healthcare professionals and professional carers. This further 
classification is based on a factual assumption that end users generally have no or less 
formal qualifications and training while the professional users are fully and properly 
qualified and skilled to use specific MDTs. In addition, they differ from each other in 
several other ways. In describing our framework, we will therefore use only two terms 
i.e. ‘end users’ and ‘professional users’ for those who employ MDTs (Figure 1).  
 
CONCEPTUAL FRAMEWORK FOR USERS’ INVOLVEMENT 
It is noteworthy that the MDTDP is an iterative process starting from idea generation 
and concept development through to device design and prototype development and 
testing, and device deployment in the market (5). We believe that the involvement of 
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users can be through an iterative process that can take place at different points in the 
MDT lifecycle (Figure 1).  We also believe that in developing a MDT there can be three 
possibilities as under. 
MDT Development Scenarios 
 Scenario A: Device New to the Market. In the case of development of a device new to 
the market, a lengthy and detailed iteration from the stage of concept development through to 
the stage of deployment / launching the device in the market will be required (Figure 2a). This 
type of device can be developed using either an existing technology or a new technology (10). 
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Figure 2a. MDT development scenario A: Device new to the market 
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Scenario B: Major Upgrade of an Existing Device. A major upgrade of an existing 
device will involve an iterative process between the design and prototype development stage, 
prototype testing and trials stage and deployment stage (Figure 2b). 
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Figure 2b. MDT development scenario B: Major upgrading of existing device 
 
 
 
 
  
 
11 
Scenario C: Redesigning of a Device Prototype. The redesigning of a device prototype 
will involve an iterative process mainly between the design and prototype development stage 
and prototype testing and trials stage (Figure 2c). For prototype redesigning, users’ ideas can be 
helpful that can be solicited through their involvement via the idea generation and concept 
development stage. 
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Figure 2c. MDT development scenario C: Redesigning of device prototype 
 
 
Bearing in mind these possible scenarios and the iterative process of developing MDTs, we 
propose a conceptual framework (Figure 1), which suggests two routes by which involvement 
of particular types of users may be exercised and various methods can be applied for involving 
users in various ways at four different stages of the device lifecycle, as follows.  
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User Involvement Streams 
In this framework (Figure 1), we suggest two routes i.e. end users’ stream and a professional 
users’ stream for involving users in the MDTDP. Each of the streams covers four stages starting 
from the idea generation and concept development, device design and prototype development, 
prototype testing and trialling through to the market deployment of the device. These four 
stages of users’ involvement are proposed for the development of a device that is new to the 
market (Scenario A) (Figure 2a). However, as we have noted, major upgrading of an existing 
device (Scenario B) will generally involve three stages i.e. designing, testing and trialling and 
deploying of the device in the market (Figure 2b), on the other hand redesigning of a prototype 
(Scenario C) will require iterative user involvement primarily between two stages i.e. the design 
and prototype development stage and the testing and trials stage; however, soliciting users’ 
opinions via the concept (idea generation) stage can be helpful (Figure 2c). The operation of the 
streams is described below. 
End Users’ Stream  
We suggest that the ‘end users’ (EU) stream (Figure 1) is deployed for the involvement of end 
users i.e. patients, persons with disabilities and/or special needs and elderly people, in addition 
to lay carers. In general, this stream would be used by MDT developers for MDTs that will be 
used only by the end users themselves, and/or their carers as proxies for them, generally 
outside clinical settings and usually at their homes. We believe that devices used by the end 
users can be relatively simple and less complex as well as more complex and/or innovative. We 
therefore put forward two device exemplars for the application of this stream. 
 
Exemplar 1. A medical device that will be used by the end user(s) and the device will 
not be very complex. For example, an inhaler device. 
In the case of this type of MDT, the developers can use the EU stream, and involve end 
users in the iterative process between various stages of the device development cycle as 
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mentioned in and depending on the MDT development scenarios described above. In developing 
this type of devices, manufacturers can involve professional users, particularly healthcare 
professionals, such as clinicians, through professional users’ (PU) stream for obtaining their 
opinions and suggestions regarding the device. 
 
Exemplar 2. A medical device that will be used by the end user(s) and the device will be 
more complex and/or innovative. For example, assistive devices such as a robotic aid. 
Developing this type of MDT, there can also be three scenarios mentioned earlier. In the 
case of developing this type of device new to the market, it is possible that the concept can come 
from the end user(s), the professional user(s) or the manufacturer. If the concept was 
developed by the end user(s) then they should be involved iteratively as described in the MDT 
development scenario A (Figure 2a) and using the EU stream (Figure 1). However, if the concept 
was developed by the professional user(s) or the manufacturer, then a model may be more 
appropriate as that in scenario 4, described under the PU stream.  
 In the case of major upgrade of this type of an existing device or redesigning of a 
prototype, end users can be involved as described in the MDT development scenario B (Figure 
2b) or scenario C (Figure 2c) respectively and through the EU stream (Figure 1). In all the three 
cases, manufacturers can involve healthcare professionals particularly clinicians, through the 
PU stream (Figure 1), at later stages i.e. testing and trials stage and deployment stage for 
obtaining their opinion and suggestions regarding the device.  
Professional Users’ Stream 
We suggest the professional users’ (PU) stream for the involvement of professional users of 
MDTs (Figure 1). We propose that this stream should be used by MDT developers for creating 
medical devices that will be used only by the professional users i.e. healthcare professionals 
and/or professional carers for treating and/or caring for an end user or inserting/implanting 
the device in to the body of an end user by a healthcare professional. 
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 In this stream, professional users can be involved in iteratively between various stages 
of the device lifecycle depending on and as mentioned in the MDT development scenarios A, B 
and C described above. In addition, there will be a need to involve the end users, at the testing 
and trials stage and the deployment stage, to check the device performance. To make the 
application of the PU stream more plausible, we put forward two device exemplars. 
 
Exemplar 3. A medical device will be used only by healthcare professional(s) for the 
treatment / diagnosis and/or care of the end user(s). For example, a neuromagentometer.  
To develop this type of device, there can be three scenarios i.e. A, B and C as mentioned 
earlier. For developing this type of device new to market (Scenario A), there can be two 
possibilities. First, if professional user(s) such as surgeon(s) developed the device concept, then 
we suggest that s/he/they should be involved from the concept development stage, through to 
device design and prototype development, testing and trials and the deployment stages of the 
device (Figure 1 & 2a). Second, if the manufacturer developed the concept, then the professional 
users may not be involved at the concept development stage but at the latter stages. We 
however suggest that they should be involved at this stage to avoid any unforeseen and 
potential limitations. For developing MDTs as mentioned in Scenario B or Scenario C, 
manufacturer can involve professional users at the stages and in the manner described in the 
respective scenarios (Figure 2b & 2c). Irrespective of the scenarios, there will however be a 
need for end users’ involvement at the testing and trials and the deployment stages to evaluate 
the device performance (Figure 1).   
 
Exemplar 4. A device will be used by the end user(s) but a healthcare professional will 
insert/place it in to the body of the end user. The device is more complex and/or innovative. For 
example, an implantable medical device. 
  There can be three scenarios i.e. A, B and C, as mentioned earlier, to develop this type of 
device. In scenario A, if the concept was developed by the healthcare professional(s) then 
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s/he/they can be involved at all four stages described in MDT development scenario A (Figures 
1 & 2a). However, if the concept for developing this type of device came from the manufacturer, 
then the manufacturer may not involve healthcare professionals at the concept stage but at the 
device design and prototype development stage through to the testing and trials and 
deployment stages (Figures 1 & 2a). We however suggest that the manufacture involves 
healthcare professional at the concept stage to discuss the device concept to thrush out any 
potential limitations. In the case of developing MDT as mentioned in scenarios B and C, 
manufacturers should involve the professional users as described in the respective scenario 
(Figures 2b & c).  Irrespective of the scenarios, there will however be a need to involve the end 
users at the testing and trials stage, and deployment stage to assess and assess the device 
performance.  
User Involvement Methods  
We suggest various methods (Figure 1) for involving both the end users and the professional 
users, using the EU stream and the PU stream respectively, in the MDTDP. The most common 
methods that we suggest for both types of the users and the streams include interviews, focus 
groups, brainstorming sessions and users-producers seminars at the concept stage; interviews, 
usability tests and users’ feedback at the design stage; usability tests, interviews and discussion 
at testing and trials stage; ethnography, interviews and surveys for (post-) deployment stage of 
the device (Figure 1). 
DISCUSSION 
Practice has been very varied in involving users in the MDTDP and sometimes user 
involvement, particularly end user involvement, is very modest. Low or limited user 
involvement could be due to a number of factors such as a lack of funds and time available to 
manufacturers who are operating in a very competitive market  (34).  It may also occur through 
the personal limitations of users (through cognitive, physical, or informational problems) to 
meaningfully participate in the MDTDP (34). Despite above-mentioned constraints, there is 
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often a willingness among manufacturers to use feedback from users’ in the development of 
MDTs. Nevertheless, there is then the poverty of effective frameworks to incorporate users’ 
feedback in the MDTDP. It is the need for such a framework that we have addressed in this 
paper. 
 We have proposed a generic theoretical framework for directly involving both the end 
users (non-professional users) and the professional users in the MDTDP (Figure 1). We 
recognise that medical devices differ from each other depending on the nature and complexity 
of the technology involved, type of the intended user, the environment and context of the use 
and the type of medical condition for which the device(s) is used.  The nature of medical devices 
and the type of the intended user are however the most critical issue in involving users in the 
MDTDP. In this framework, we have therefore suggested two routes i.e. EU stream and PU 
stream (Figure 1) through which needs of the intended users can be incorporated in the 
MDTDP.  
 In our framework, we have proposed that if the medical device being developed is a 
simple device that will be used by the end users then the EU stream will be the first choice to 
develop such device. This is because end users know their needs better than any body else. In 
addition, we assume, end users, and their lay carers, might already have used a similar device at 
some point in time; therefore, they may have experience and knowledge of the limitations of 
using such a device. End users therefore can be helpful in (re)designing and/or upgrading of 
existing devices as well as developing a new device that can be used for a similar purpose. It is 
also possible that healthcare professionals, and professional carers, can convey some of the 
needs and requirements of the end users, which they have come to know often through early 
contact with some of the end users. Manufacturers can therefore also involve professional users 
through the PU stream to get their perspectives about the device. An example is the 
development of an inhaler by Anderson et al (1), who involved both the end users i.e. asthma 
patients and their lay carers, and professional users i.e. physicians, general practitioners and 
asthma nurses from the concept and design development stages through to the testing and trials 
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stages and their perspectives were obtained by various methods, such as interviews, focus 
groups, usability tests and user feedback.  
  Our framework suggests that if the MDT being developed is both complex and/or 
innovative, which is to be used by either the end user or the professional user, and a healthcare 
professional, a professional carer, and/or a manufacturer suggested the concept, then the PU 
stream should be the first choice to develop such device. Nevertheless, the involvement of end 
users will be required at the later stages in particular during testing and trialing stage and at the 
stage of device deployment in the market to assess and evaluate the device performance. For 
example, involvement of both healthcare professionals and end users in the development 
process of a neuromagnetometer – a complex device that is used by healthcare professionals for 
the analysis of the human cortex (brain) activity in patients with certain medical conditions, 
such as  epilepsy and brain tumours (17;27). There is a further example of such a deployment in 
relation to a complex and innovative device developed through users’ involvement, which is the 
Gynecare TVT Secure System device for female stress urinary incontinence. This device was 
primarily developed by involving mainly professionals staff such as uro-gynaecologists and 
urologists, a primary route similar to the PU stream suggested in our framework, while end 
users (female patients with stress urinary incontinence) were used at the testing and trialing 
stage and deployment stage, a secondary route similar to that proposed in the EU stream 
mentioned in our framework (Personal email communication from Peter A. Meier, Principal 
Scientist, Research & Development, ETHICON GmbH, Germany). It is important to bear in mind 
that end users may not possess sufficient technical knowledge and understanding about such 
complex products to be able to fully give incisive assessments about them. Manufacturers 
therefore should not expect end users to solve major technical problems, therefore their 
involvement should be mainly for the purpose of identifying and clarifying their requirements 
and the vital features of the devices for them (21). Nevertheless, for innovative devices such as 
in relation to emerging medical technologies, end users can still be extensively involved at the 
testing stage of the device prototype (6).  
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 We do not prescribe specific method(s) for involving the users at any point in the 
MDTDP because we believe that the selection of those particular method(s) depends upon the 
resources, both money and time, and expertise available to the MDT developer. Developers 
should therefore decide themselves whether to use any particular method, taking into account 
costs and resources available, together with the type of data required and the quality of 
information obtainable through the method. There is no doubt that the involvement of users in 
developing MDT is a protracted process; nevertheless, its impact on the device development is 
very great (6). “The manufacturers therefore need to build-in time and resource for such 
activities into the development plan and ensure end-user as well as professional-user value is 
captured in the product's value proposition” (Personal email communication by Michael 
Borroff, Director of Strategic Health Outcomes, DePuy International). 
Limitations. The authors recognise limitations of this framework such as the need for 
its validation, which will be undertaken in collaboration with our industrial partners, and the 
generality in its description. The latter is however done purposely to provide a generic 
framework and for ensuring involvement of different types of MDT users and to present it as an 
easily understood approach for managers in the medical device manufacturing industry. 
POLICY IMPLICATIONS  
According to Marshall et al (24), a ‘designing for all’ approach is required in product 
development to meet the needs of users particularly the needs of specific groups of end users. 
The PU stream is the most widely used route of users’ involvement by the majority of device 
manufacturers. This practice has led medical research to be biased in favour of professional 
users, essentially only doctors / clinicians (30). We therefore would like to draw attention to a 
few important issues in this regard. Firstly, manufacturers must involve potential users, be they 
patients, healthcare professionals or carers who are actually going to use the device. Secondly, 
members of R&D staff within manufacturing companies must not be assumed to predict 
accurately actual users’ needs. Hence, it is unwise they should be involved as a total proxy on 
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behalf of the real users of the device. Nevertheless, there are exceptions, for example if a 
particular member of R&D who has ever used a device in his/her capacity either as a healthcare 
professional, caregiver or patient then he/she might be suitable to be involved in the 
development of such device and represent users’ needs. Our framework (Figure 1) therefore 
ensures the involvement of different types of the medical device users to meet their specific and 
often hitherto unmet needs and requirements. Development of this conceptual work will 
support MDT manufacturers, particularly small and medium manufacturers (SMMs), who may 
have limited expertise with regard to engagement with users, especially end users, in 
developing decision-making protocols regarding users’ involvement in the MDTDP. 
CONCLUSION 
The development and evaluation of medical devices from users’ perspectives requires not only 
the involvement of healthcare professionals but also that of the ultimate end users i.e. patients, 
people with disabilities and/or special needs, and their lay caregivers. This is because the needs 
of various types of the users vary widely from each other. The evidence shows that such end 
users quickly discard devices that do not fulfil their personal expectations, even though both 
manufacturers and healthcare professionals may consider those end users’ requirements met. 
MDT developers and manufacturers need to recognise this potent potential discrepancy 
between the parties involved, and involve end users as well as professional healthcare staff 
directly in the MDTDP. Nevertheless, the engagement of some types of medical device users, 
particularly end users may not always be possible for various reasons such as a lack of formally 
defined user involvement process, hence more formal approaches and a generic framework for 
involving end users needs to be developed and refined. The availability of a user involvement 
framework such as that proposed in this paper will help medical device manufacturers, 
particularly SMMs, in planning and developing strategies for involving end users and 
professional users in the MDTDP. 
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